NCT05686759View on ClinicalTrials.gov

A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.

PHASE3RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

April 13, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Undiluted I.V.-Hepabig inj(GC5103)

undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

BIOLOGICAL

Diluted I.V.-Hepabig inj(GC5103)

Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit

Trial Locations (8)

10408

RECRUITING

National Cancer Center, Goyang-si

16499

RECRUITING

Ajou University Medical Center, Suwon

35015

RECRUITING

Chungnam National University Hospital, Daejeon

48108

RECRUITING

Inje University Haeundae Paik Hospital, Busan

05505

RECRUITING

Asan Medical Center, Seoul

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

GC Biopharma Corp
All Listed Sponsors
lead

GC Biopharma Corp

INDUSTRY

NCT05686759 - A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. | Biotech Hunter | Biotech Hunter